Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence

B izollon, T.; Ahmed, S.N.S.; Radenne, S.; Chevallier, M.; Chevallier, P.; Parvaz, P.; Guichard, S.; Ducerf, C.; Baulieux, J.; Zoulim, F.; Trepo, C.
February 2003
Gut;Feb2003, Vol. 52 Issue 2, p283
Academic Journal
Background and objective: A proportion of liver transplanted patients with recurrent chronic hepatitis have a sustained virological response to combination therapy with interferon plus ribavirin. However, the long term benefit of antiviral therapy with regard to hepatitis C virus (HCV) RNA clearance remains unknown in patients with HCV recurrence. This study examined the long term biochemical, virological, and histological outcome in transplanted patients with recurrent chronic hepatitis who had a sustained virological response to antiviral therapy. Patients and methods: Fifty four patients with recurrent hepatitis C were treated with antiviral therapy involving induction by combination therapy (interferon (IFN) plus ribavirin) for six months and maintenance ribavirin therapy for 12 months. Fourteen patients who had recurrent chronic hepatitis and sustained virological response to antiviral therapy were followed for three years after the end of antiviral therapy. Serum alanine aminotransferases were assessed every three months during the observation period. Serum hepatitis C RNA detected by polymerase chain reaction was evaluated every six months during follow up, and protocol biopsy procedures were performed routinely every year. Semiquantitarive histopathological assessment of allograft hepatitis was performed using the Knodell score and HCV was also detected by polymerase chain reaction on frozen graft tissue samples. Results: At the end of antiviral therapy, the sustained response rate was 26%. A complete response (normal serum alanine aminotransferase level and undetectable serum HCV RNA) was achieved in 13/14 (93%) patients three years after the end of treatment. A comparison of liver histology findings before and after a mean of three years after antiviral therapy showed a clear improvement in 12/14 (86%) patients. In 5/14 (36%) patients, the last biopsy showed normal or near normal histological findings. After three years of follow up, the total Knodell...


Related Articles

  • On multi-strain model for Hepatitis C.  // Nonlinear Biomedical Physics;2011, Vol. 5 Issue 1, p6 

    The article offers information on the multi-strain model for hepatitis C virus (HCV), which also represents the basic properties of the immune system. It states that chronic HVC infection leads to liver transplant or death, while antiviral therapy is used to treat patients with HVC. It mentions...

  • Late Mortality from Thrombotic Microangiopathy After Liver Transplantation: Report of a Case. Nobuhisa Akamatsu; Yasuhiko Sugawara; Sumihito Tamura; Junichi Togashi; Junichi Kaneko; Masatoshi Makuuchi // Surgery Today;Apr2007, Vol. 37 Issue 4, p345 

    Abstract  Thrombotic microangiopathy (TMA) after liver transplantation is thought to be a rare event. We report a case of TMA after living donor liver transplantation for hepatitis C virus-related cirrhosis. The patient was initially placed on a tacrolimus-based immunosuppressive...

  • The economic burden of advanced liver disease among patients with Hepatitis C Virus: a large state Medicaid perspective. Menzin, Joseph; White, Leigh Ann; Nichols, Christine; Deniz, Baris // BMC Health Services Research;2012, Vol. 12 Issue 1, p459 

    Background: Chronic hepatitis C virus (HCV) may progress to advanced liver disease (ALD), including decompensated cirrhosis and/or hepatocellular carcinoma (HCC). ALD can lead to significant clinical and economic consequences, including liver transplantation. This study evaluated the health care...

  • Hepatitis C Treatment: Trial by Design. Bzeizi, Khalid I. // Saudi Journal of Gastroenterology;Apr-Jun2008, Vol. 14 Issue 2, p51 

    The author comments on the findings of a study about the treatment outcome of 335 hepatitis C virus (HCV) patients treated with peginterferon α-2a and ribavirin combination therapy in Saudi Arabia. He states that the divergence of the study's findings from the prospective studies published...

  • Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C. Figlerowicz, Magdalena; Sluzewski, Wojciech; Kowala-Piaskowska, Arleta; Mozer-Lisewska, Iwona // European Journal of Pediatrics;2004, Vol. 163 Issue 4/5, p265 

    Reports on the effect of interferon alpha and ribavirin in the treatment of children with chronic hepatitis C. Study of children with chronic hepatitis C; Criteria of study including detection of anti-HCV antibodies and HCV RNA in serum; Lack of correlation between patient's characteristics and...

  • Combination therapy with interferon-α and ribavirin as immunomodulators in patients with chronic hepatitis C. Horiike, Norio; Onji, Morikazu // Journal of Gastroenterology;2003, Vol. 38 Issue 3, p302 

    Editorial. Comments on the combination therapy with interferon-alpha and ribavirin as immunomodulators in patients with chronic hepatitis C virus. Effectiveness of interferon therapy for the treatment of chronic hepatitis C (CHC); Four possible mechanisms of rivirin in CHC; Role of ribavirin...

  • Immunological predictors of different responses to combination therapy with interferon α and ribavirin in patients with chronic hepatitis C. Amaraa, Ravdan; Mareckova, Helena; Urbanek, Petr; Fucikova, Terezie // Journal of Gastroenterology;2003, Vol. 38 Issue 3, p254 

    Background: This study aimed to investigate peripheral blood CD4+ T-helper (Th) and CD8+ cytotoxic T-lymphocyte (CTL) responses to combination treatment with interferon (IFN) α and ribavirin in 59 patients with chronic hepatitis C, and to correlate the results with the therapy outcome....

  • Hepatitis C costs to soar. Zolkos, Rodd // Business Insurance;07/10/2000, Vol. 34 Issue 28, p1 

    Focuses on the impact of the prevalence of hepatitis C patients on the health care costs in the United States. Implications for early treatment of the disease; Total annual health care costs for hepatitis C patients; Cost-effectiveness of the Interferon-Alfa and ribavirin combination therapy.

  • Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1. Lok, Anna S.; Gardiner, David F.; Lawitz, Eric; Martorell, Claudia; Everson, Gregory T.; Ghalib, Reem; Reindollar, Robert; Rustgi, Vinod; McPhee, Fiona; Wind-Rotolo, Megan; Persson, Anna; Zhu, Kurt; Dimitrova, Dessislava I.; Eley, Timothy; Guo, Tong; Grasela, Dennis M.; Pasquinelli, Claudio // New England Journal of Medicine;1/19/2012, Vol. 366 Issue 3, p216 

    Background: Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addition of multiple direct-acting antiviral agents to their treatment regimen. Methods: This open-label, phase 2a study included an...


Read the Article


Sign out of this library

Other Topics